A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.
about
Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsMoving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trialA randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities.HIV-associated lipodystrophy: impact of antiretroviral therapy.Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trialHIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.Dual antiretroviral therapy for HIV infection.Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: WeeEfficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database.Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease.Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trialTwo-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy
P2860
Q26768591-190C0951-1420-4EBC-ADA4-236827E425A6Q28540037-2EE16AD7-DFE9-45CE-A42F-EBA86CF990FBQ33763511-C082648D-5B50-4D67-B44C-79E8C5C29268Q34655845-21F36631-99AA-4176-9D8D-3288C9A4674DQ34952127-6C924D67-E5FD-44A4-94C8-C2508550D915Q35035055-0275C17B-9FFD-4752-8E95-101D4EC0AB1AQ35186842-15104257-C4C5-4AED-9FE7-A1A2F6531D82Q36102240-953F61E2-C261-4A4A-B4C5-C745B2C5C3B7Q36311127-DC8E1C9F-3444-4B48-BEE8-E5DF54EDACEAQ36426953-9A3DF094-60B1-4BF9-A888-DCCCF3F81BEBQ36721002-8C6457EE-CC50-4657-A609-C7C954D9CC9BQ36901564-3B26FF6F-8126-48F5-8D78-C4D7CEB5C4A1Q38170576-7B8C137A-BF1F-4C46-AA2D-AC5D05230779Q38670305-A0D8AAED-F0CC-4AA8-B7B5-AA07148D9D71Q38737182-E4229537-21A6-4FC3-A575-A468BAF78207Q38818789-DAB5EF28-9066-438F-B220-6CA45E6EDE3AQ39352442-95EF4C15-A37E-414F-A96F-30C1A42DB812Q41056086-99468586-1D4C-4318-9A1F-03F1D6D1BD90Q41372231-8AD8C97E-35EA-47BE-9471-CECE06E46D1EQ41758070-0F696D05-7AA2-4D2A-9B6D-E0EB4E84D137Q42198834-FC0CA47A-D930-45D7-AC7C-5AC0C74ED94FQ58774718-57F4E31A-9ADF-489D-90CE-48D7CFDE3F6CQ59135174-B8BBFB75-86B4-44B5-BBF6-CC7B08C4AE6C
P2860
A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A switch in therapy to a rever ...... afety profile: the KITE study.
@ast
A switch in therapy to a rever ...... afety profile: the KITE study.
@en
type
label
A switch in therapy to a rever ...... afety profile: the KITE study.
@ast
A switch in therapy to a rever ...... afety profile: the KITE study.
@en
prefLabel
A switch in therapy to a rever ...... afety profile: the KITE study.
@ast
A switch in therapy to a rever ...... afety profile: the KITE study.
@en
P2093
P2860
P356
P1476
A switch in therapy to a rever ...... afety profile: the KITE study.
@en
P2093
Anandi N Sheth
Carlos Del Rio
Ighovwerha Ofotokun
Jeffrey L Lennox
Kelly White
Kirk A Easley
Molly E Eaton
Neeta Shenvi
Sara E Sanford
P2860
P304
P356
10.1089/AID.2011.0336
P577
2012-04-20T00:00:00Z